PAR 2.04% 24.0¢ paradigm biopharmaceuticals limited..

Community Adoption / Mr Federer, page-77

  1. 572 Posts.
    lightbulb Created with Sketch. 55
    Denial - I get what you're saying but my point is that until there is a statistically significant result - those "averages" are just down to chance and can be just down to luck and randomisation. While some people may still believe there to be a DMOAD benefit, the drug label and therefore partners will not / they can't.

    As for your second question re professional indemnity. It's the same result as above. It's a moot point unless you can get something on a label, but if you are talking purely on pain and function which PPS at least seems to have some evidence of (mind you in a smaller population ((mild to mid pain patients only)), then yeah sure - but then you're just competing in a low price arena against $1 tablets which are easily prescribed and dispensed versus an injectable multiple times a week and requiring physician visits. Further to this, I personally haven't seen any studies proving that these other drugs (NSAIDS, OPIOIDS, HA, etc etc) accelerates the underlying pathology on a long-term basis aside from what mgmt have said.


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
-0.005(2.04%)
Mkt cap ! $83.98M
Open High Low Value Volume
25.0¢ 25.5¢ 24.0¢ $202.2K 814.1K

Buyers (Bids)

No. Vol. Price($)
5 181098 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 118621 5
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.